Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.51 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906190 | 0.83 | TSHR (0.47) | ALDH1A1 | |
| SCHEMBL8228565 | 0.80 | ALDH1A1 (0.53) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| SCHEMBL8707008 | 0.80 | ALDH1A1 (0.53) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| SCHEMBL6959620 | 0.80 | ALDH1A1 (0.53) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| SCHEMBL21063690 | 0.80 | ELANE (0.55) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| SCHEMBL21063692 | 0.80 | ELANE (0.55) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL25265036 | 0.79 | ALDH1A1 (0.51) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| SCHEMBL21445353 | 0.79 | ALDH1A1 (0.51) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL8712756 | 0.79 | ALDH1A1 (0.51) | ELANEPRTN3IL1RNERAP2ERAP1 | |
| SCHEMBL6959614 | 0.79 | ALDH1A1 (0.51) | ELANEPRTN3IL1RNERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198445-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | ELANE 2507/4885PRTN3 4081/4885IL1RN 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.